childhood-diabetes.org.uk
UK Children's Diabetes Research: UK GRID: Genetic Resource Investigating Diabetes
http://www.childhood-diabetes.org.uk/grid.shtml
UK Children's Diabetes Research. UK GRID: Genetic Resource Investigating Diabetes. What is the UK GRID? National DNA Collection - The Genetics of Type 1 Diabetes. Aims of the study. Access to data and samples. Oxford Regional Prospective Study, ORPS and Nephropathy Family Study, NFS. What is the UK GRID? Professor David Dunger) and Medical Genetics. In the Cambridge Institute for Medical Research. Professor John Todd) and is funded by the Juvenile Diabetes Research Foundation ( International link. We aim...
clinical-trials-type1-diabetes.com
Healthcare Professionals | DILT1D
http://www.clinical-trials-type1-diabetes.com/healthcare-professionals
If you’re a healthcare professional and require further information or would like to refer a patient please contact Dr Frank Waldron-Lynch. ClinicalTrials.gov Identifier: NCT02265809. UK Clinical Research Network: 17571. Heywood J, Evangelou M, Goymer D, et al. Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). By the S...
clinical-trials-type1-diabetes.com
Home | DILT1D
http://www.clinical-trials-type1-diabetes.com/home
This research is sponsored by Cambridge University Hospitals NHS Foundation Trust. And the University of Cambridge. With funding from a grant provided to the JDRF /Wellcome Trust Diabetes and Inflammation Laboratory (DIL). By the Sir Jules Thorn Charitable Trust. Contributions also acknowledged from the NIHR Cambridge BioMedical Research Centre.
clinical-trials-type1-diabetes.com
About DILfrequency | DILT1D
http://www.clinical-trials-type1-diabetes.com/about-us-2
Aptive study of IL. On regulatory T cells in T. Type 1 diabetes is the most common severe chronic autoimmune disease worldwide and the incidence of the disease is rising rapidly. Type 1 diabetes causes the immune system to mistake cells in the pancreas as harmful and attack them. When these cells are damaged the pancreas is unable to produce insulin, which plays an essential role in transferring glucose out of the bloodstream and into cells to be converted into energy. Page or watch the videos below.
clinical-trials-type1-diabetes.com
Study Location | DILT1D
http://www.clinical-trials-type1-diabetes.com/study-location
The main study visits will be held at the NIHR Wellcome Trust Clinical Research Facility. Level 5), Box 127, Addenbrooke’s Hospital, Cambridge, CB2 0QQ. The NIHR Wellcome Trust Clinical Research Facility is located within the Addenbrooke’s Centre for Clinical Investigation (ACCI) building on the Addenbrooke’s hospital site. For more information about getting to Addenbrooke’s Hospital. This page also includes information on parking and bus timetables. And the University of Cambridge.
clinical-trials-type1-diabetes.com
The Team | DILT1D
http://www.clinical-trials-type1-diabetes.com/the-team
To contact a member of the team please email: DILT1D@cimr.cam.ac.uk. Or telephone 01223 762327. Websites: http:/ www.immunology.cam.ac.uk/directory/Frank.Waldron-Lynch@cimr.cam.ac.uk. Https:/ www-gene.cimr.cam.ac.uk/. Website: http:/ www.immunology.cam.ac.uk/directory/truman. Mark Evans is a Clinical Lecturer and Researcher at The Institute of Metabolic Science, University of Cambridge and Honorary Consultant Physician at Addenbrooke’s Hospital. He specialises in the treatment of type 1 diabetes and ...
clinical-trials-type1-diabetes.com
Am I Eligible? | DILT1D
http://www.clinical-trials-type1-diabetes.com/am-i-eligible
You may be eligible to participate in the DILfrequency if you:-. 8211; Are aged 18-70 and. 8211; Diagnosed with type 1 diabetes in the past 5 years. To register your interest in the study or receive further information please call or email the DILfrequency team at DILT1D@cimr.cam.ac.uk. Page The chief investigator Dr Frank Waldron-Lynch. Or a member of the DILfrequency team will be in touch. This research is sponsored by Cambridge University Hospitals NHS Foundation Trust. And the University of Cambridge.
clinical-trials-type1-diabetes.com
Previous Studies | DILT1D
http://www.clinical-trials-type1-diabetes.com/previous-studies
Aptive study of IL. 2 dose on regulatory T. Cells in type 1. Type 1 diabetes is the most common severe chronic autoimmune disease worldwide and the incidence of the disease is rising rapidly. Type 1 diabetes causes the immune system to mistake cells in the pancreas as harmful and attack them. When these cells are damaged the pancreas is unable to produce insulin, which plays an essential role in transferring glucose out of the bloodstream and into cells to be converted into energy. Waldron-Lynch F, Karec...